Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

First came the slow hand movements, then the tremor, and now the looming fear of what lies ahead. By the end of the decade, ...

A 47-year-old man was the first in the world to be treated outside of a study context with a new technique for the symptoms ...

Michael J. Fox made an appearance over the weekend at the Fan Expo in New Orleans, alongside his cast members from the Back ...

Neurological conditions are now the leading cause of ill health worldwide, yet remain an enigma. Meet the patients who baffle ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

In Episode 746 of Power Athlete Radio, Dr. Adeel Khan dives into cutting-edge advancements in regenerative medicine, focusing on induced pluripotent stem cells ...

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose ...

Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Enrollment ongoing in the United States for REGENERATE-PD clinical trial of AB-1005 ...

Chantal Theriault is inviting the community to join her for the 2nd annual Kick it for Parkinson’s fundraiser at Therien ...

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.